Novavax initiates phase 2 clinical trial of RSV F-protein nanoparticle vaccine candidate
Novavax announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate, in healthy women in the third trimester of pregnancy. The study is a randomized, blinded, placebo-controlled Phase 2 study. September 16, 2014